DUBLIN–(BUSINESS WIRE)–The “Cell and Gene Therapy Contract Development and Manufacturing Organizations, 2022: Frost Radar Report” report has been added to ResearchAndMarkets.com’s offering.
As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treatment. Some organizations double up as hybrid CDMOs and incubators.
They have their own pipelines, but they also partner with other companies to support and accelerate development.
Contract development and manufacturing organizations (CDMOs) and CROs are expanding organically and inorganically to provide end-to-end CGT services. More than 100 companies compete in the CGT CDMO marketplace globally, and most specialize in either cell therapy or gene therapy. Only a handful offer diversified services. CDMOs are increasingly distinguishing themselves from their competitors and have redefined themselves as contract research, development, and manufacturing organizations (CRDMOs) and have integrated themselves into companies’
value chains.
The Frost RadarT reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the
Frost RadarT methodology. The document presents competitive profiles of each of the companies in the Frost RadarT based on their strengths, opportunities, and a small discussion on their positioning. The analyst analyzes hundreds of companies in an industry and benchmarks them across 10 criteria on the Frost RadarT, where the leading companies in the industry are then positioned.
Key Topics Covered:
1. Strategic Imperative and Growth Environment
- Strategic Imperative
- Growth Environment
2. Frost RadarT
- Frost RadarT: Cell and Gene Therapy CDMOs
- Frost RadarT: Competitive Environment
3. Companies to Action
- AGC Biologics
- Catalent
- Charles River Laboratories
- Lonza
- Merck KGaA
- Minaris Regenerative Medicine
- RoslinCT
- Thermo Fisher Scientific
- WuXi Advanced Therapies
4. Strategic Insights
5. Next Steps: Leveraging the Frost RadarT to Empower Key Stakeholders
- Significance of Being on the Frost RadarT
- Frost RadarT Empowers the CEO’s Growth Team
- Frost RadarT Empowers Investors
- Frost RadarT Empowers Customers
- Frost RadarT Empowers the Board of Directors
6. Frost RadarT Analytics
- Frost RadarT: Benchmarking Future Growth Potential
Companies Mentioned
- AGC Biologics
- Catalent
- Charles River Laboratories
- Lonza
- Merck KGaA
- Minaris Regenerative Medicine
- RoslinCT
- Thermo Fisher Scientific
- WuXi Advanced Therapies
For more information about this report visit https://www.researchandmarkets.com/r/9bhjeh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
